Distribution of tumor location (primary, metastatic, or unknown) was similar for the assessment of each biomarker (HER2 mRNA, HER3 mRNA, PIK3CA status, and PTEN) and was well balanced across the three treatment arms (data not shown). This evidence concerns the gene ERBB2 and neoplasm.